Table 2 |
||||||
|
Distribution of breast cancer tumor subtypes by race/ethnicity in the combined LACE and Pathways Studies (n = 2544) |
||||||
|
Tumor subtype |
White n (%) |
African American n (%) |
Asian n (%) |
Hispanic n (%) |
Other n (%) |
P valuea |
|
|
||||||
|
Luminal A (ER+ and/or PR+, Her2-) n = 1868 (73.4) |
1464 (75.3) |
92 (59.4) |
135 (71.4) |
135 (68.5) |
37 (68.5) |
0.0001 |
|
Luminal B (ER+ and/or PR+, Her2+) n = 294 (11.6) |
215 (11.1) |
14 (9.0) |
30 (15.9) |
28 (14.2) |
7 (13.0) |
0.18 |
|
Triple negative (ER-, PR-, Her2-) n = 288 (11.3) |
204 (10.5) |
44 (28.4) |
12 (6.3) |
21 (10.7) |
7 (13.0) |
< 0.0001 |
|
Her2 overexpressing (ER-, PR-, Her2+) n = 94 (3.7) |
60 (3.1) |
5 (3.2) |
12 (6.4) |
13 (6.6) |
3 (5.5) |
0.03 |
|
|
||||||
|
Total n = 2544 (100) |
1943 (100) |
155 (100) |
189 (100) |
197 (100) |
54 (100) |
--- |
|
|
||||||
|
a From Pearson chi-square test across racial/ethnic categories. ER = estrogen receptor; Her2 = human epidermal growth receptor 2; PR = progesterone receptor; + = positive; - = negative. |
||||||
|
Kwan et al. Breast Cancer Research 2009 11:R31 doi:10.1186/bcr2261 |
||||||
